Brown Brothers Harriman & Co. Grows Stock Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Brown Brothers Harriman & Co. increased its holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 88.2% in the 3rd quarter, HoldingsChannel reports. The fund owned 143,051 shares of the company’s stock after purchasing an additional 67,027 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in TScan Therapeutics were worth $712,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP acquired a new position in shares of TScan Therapeutics in the 2nd quarter valued at $70,000. SG Americas Securities LLC purchased a new stake in TScan Therapeutics in the 3rd quarter valued at about $78,000. The Manufacturers Life Insurance Company acquired a new position in TScan Therapeutics in the second quarter valued at about $90,000. Cornercap Investment Counsel Inc. purchased a new position in TScan Therapeutics during the second quarter worth about $134,000. Finally, Rhumbline Advisers acquired a new stake in shares of TScan Therapeutics during the second quarter valued at about $274,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

Insider Activity

In other news, Director Barbara Klencke bought 5,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The shares were purchased at an average cost of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the purchase, the director now owns 45,000 shares of the company’s stock, valued at approximately $238,050. This represents a 12.50 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.76% of the company’s stock.

TScan Therapeutics Trading Up 2.7 %

NASDAQ TCRX opened at $4.64 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The firm has a 50 day simple moving average of $5.12 and a 200-day simple moving average of $6.28. TScan Therapeutics, Inc. has a one year low of $3.92 and a one year high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, equities analysts forecast that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

Analysts Set New Price Targets

TCRX has been the topic of several recent analyst reports. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a report on Tuesday, November 12th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research note on Friday, November 15th. Finally, Wedbush restated an “outperform” rating and set a $10.00 price target on shares of TScan Therapeutics in a research report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, TScan Therapeutics currently has a consensus rating of “Buy” and an average price target of $12.00.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.